Acquiring Company
Intas Pharmaceuticals Ltd
Acquired Company
Coherus BioSciences
Ahmedabad
Redwood CityManufacturingBiotechnologyHealth CarePharmaceuticalBiotechnologyHealthcareDescription
Intas Pharmaceuticals has successfully completed its acquisition of the UDENYCA® franchise from Coherus BioSciences, Inc. This acquisition enhances Accord BioPharma's position in the U.S. biosimilar market. UDENYCA® is a pivotal treatment for patients undergoing chemotherapy. The integration of Coherus employees into Accord BioPharma is expected to strengthen the company's capabilities.
Quick answer
Intas Pharmaceuticals Ltd is acquiring Coherus BioSciences, announced April 14, 2025. Intas Pharmaceuticals Ltd is based in Ahmedabad, Gujarat, India.
- How much did Intas Pharmaceuticals Ltd pay for Coherus BioSciences?
- The deal value was not disclosed.
- What does Intas Pharmaceuticals Ltd do?
- Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India.
- Where are Intas Pharmaceuticals Ltd and Coherus BioSciences based?
- Intas Pharmaceuticals Ltd is based in Ahmedabad, Gujarat, India. Coherus BioSciences is based in Redwood City, California, United States.
- Who are the decision-makers at Intas Pharmaceuticals Ltd?
- Fundz holds 4 contacts at Intas Pharmaceuticals Ltd. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Healthcare
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Cerevel Therapeutics for $45 per share (May 28, 2025)
- AbbVie to acquire Cerevel for $45 per share (April 15, 2025)
- AbbVie acquires Cerevel Therapeutics for $45 per share (March 31, 2025)
- Roquette acquires IFF Pharma Solutions for growth (May 5, 2025)
- Apnimed acquires global rights to sulthiame (April 25, 2025)
- Hikma acquires ANDA for trametinib from Novugen (April 17, 2025)
Who to call at Intas Pharmaceuticals Ltd, and when
When Intas Pharmaceuticals Ltd changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Intas Pharmaceuticals Ltd raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Intas Pharmaceuticals Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Intas Pharmaceuticals Ltd. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Intas Pharmaceuticals Ltd makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Coherus BioSciences?
Coherus BioSciences was acquired by Intas Pharmaceuticals Ltd, based in Ahmedabad. The deal was reported on April 14, 2025. Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India. Intas Pharmaceuticals Ltd is privately held and operates in Manufacturing.
When did Intas Pharmaceuticals Ltd acquire Coherus BioSciences?
Intas Pharmaceuticals Ltd's acquisition of Coherus BioSciences was reported on April 14, 2025. Intas Pharmaceuticals has successfully completed its acquisition of the UDENYCA® franchise from Coherus BioSciences, Inc. This acquisition enhances Accord BioPharma's position in the U.S. biosimilar market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Coherus BioSciences do?
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. It is privately held, operating in Biotechnology, and is based in Redwood City.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.